Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.42 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 3/20 | 0.35 |
| ▸ | ENO1 | P06733 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18651089 | 0.86 | PRKCA (0.37) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL681950 | 0.86 | PRKCA (0.46) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL12345780 | 0.84 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL5534787 | 0.81 | PRKCA (0.43) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL11987677 | 0.80 | — | — | |
| SCHEMBL15472935 | 0.79 | PRKCA (0.42) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL434232 | 0.79 | PRKCA (0.42) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL47526 | 0.78 | CYP4F2 (0.37) | CYP4F2CYP4A11 | |
| SCHEMBL12345969 | 0.78 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL15424775 | 0.77 | PRKCA (0.41) | PRKCABTN3A1ALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230293569-A1 | MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-09-21 | — | — | US | disclosed |
| US-20230158053-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| EP-3738969-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES FOR USE IN TREATING PNEUMOVIRINAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20180201577-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-19 | — | — | US | disclosed |
| US-10017491-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180186807-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | BIOPHARMA CREDIT PLC (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20180147227-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2018-05-31 | — | — | US | disclosed |
| US-9981939-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-7427636-B2 | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080167270-A1 | ANTI-INFECTIVE PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2008-07-10 | — | — | US | disclosed |
| US-20080107628-A1 | Polymerase inhibitors | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20080008682-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2008-01-10 | — | — | US | disclosed |
| US-7300924-B2 | Anti-infective phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| WO-2007027248-A2 | 3', 5' - CYCLIC NUCLEOSIDE ANALOGUES FOR TREATMENT OF HCV | VALEANT RESEARCH & DEVELOPMENT (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-4495180-A | Prodrugs of Ara-A an antiviral agent | MERCK & CO., INC. (US) | 1985-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158053-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | PRKCA 1552/4885BTN3A1 3911/4885ALDH1A1 1078/4885 |
| US-20080167270-A1 | ANTI-INFECTIVE PHOSPHONATE ANALOGS | PHOSPHO1, PGLS, PSPH | PRKCA 1219/4885BTN3A1 3066/4885ALDH1A1 4791/4885 |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | PRKCA 1592/4885BTN3A1 2743/4885ALDH1A1 1089/4885 |
| US-20080107628-A1 | Polymerase inhibitors | POLR2H, POLR2E, POLR1E | PRKCA 2662/4885BTN3A1 4694/4885ALDH1A1 1919/4885 |
| US-20180201577-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | PRKCA 1592/4885BTN3A1 2743/4885ALDH1A1 1089/4885 |
| US-20180147227-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | PRKCA 1552/4885BTN3A1 3911/4885ALDH1A1 1078/4885 |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | PRKCA 1530/4885BTN3A1 4281/4885ALDH1A1 1927/4885 |
| US-20230293569-A1 | MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME | NAMPT, NUDT15, NME4 | PRKCA 2458/4885BTN3A1 4049/4885ALDH1A1 2811/4885 |
| US-20180186807-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | PRKCA 1592/4885BTN3A1 2743/4885ALDH1A1 1089/4885 |
| US-20080008682-A1 | Modulators of toll-like receptor 7 | TLR7, TLR6, TLR3 | PRKCA 1401/4885BTN3A1 3802/4885ALDH1A1 3629/4885 |
| US-10017491-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | PRKCA 1592/4885BTN3A1 2743/4885ALDH1A1 1089/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | PRKCA 1829/4885BTN3A1 3617/4885ALDH1A1 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.